Top

Cancer Chemotherapy and Pharmacology

Published in:

01-08-2014 | Original Article

Cimetidine attenuates vinorelbine-induced phlebitis in mice by militating E-selectin expression

Authors: Zhuo Wang, Lijuan Ma, Xuebin Wang, Heping Cai, Jin Huang, Jiyong Liu, Jinhong Hu, Dingfeng Su

Published in: Cancer Chemotherapy and Pharmacology | Issue 2/2014

Abstract

Purpose

We investigated E-selectin expression in mice and rabbits with vinorelbine-induced phlebitis and the effect of cimetidine. To find the relationship between E-selectin expression and vinorelbine-induced phlebitis.

Methods

Mouse and rabbit model of vinorelbine-induced phlebitis was established by intravenous infusion of vinorelbine. Pathological observation, molecular-biological determination of E-selectin and protein function of it was evaluated.

Results

Grossly, we observed swelling, edema and cord-like vessel changes in mice receiving vinorelbine but only mild edema in mice pretreated with cimetidine. Pathological scoring yielded a total score of 37 for vinorelbine-treated mice and 17 for mice pretreated with cimetidine (P < 0.05). ELISA revealed that rabbits treated with vinorelbine had markedly higher serum contents of E-selectin than normal saline (NS) controls (vinorelbine 1.534 ± 0.449 vs. NS 0.746 ± 0.170 ng/mL, P < 0.05), which was markedly attenuated by cimetidine (cimetidine 0.717 ± 0.468 vs. vinorelbine 1.534 ± 0.449 ng/mL, P < 0.05). Rose Bengal staining assays showed that vinorelbine markedly increased the adhesion rate of neutrophils for endothelial cells (vinorelbine 38.70 ± 8.34 % vs. controls 8.93 ± 4.85 %, P < 0.01), which, however, was significantly suppressed by cimetidine (9.93 ± 5.91 %, P < 0.01 vs. vinorelbine). In E-selectin knockout mice, we found no apparent difference in tail swelling in mice receiving vinorelbine or cimetidine and vinorelbine.

Conclusions

In conclusion, cimetidine attenuates vinorelbine-induced phlebitis in mice probably by suppressing increased expression of E-selectin.

Myrianthefs P, Karatzas S, Baltopoulos G (2005) Complications, thrombophlebitis rates, and intravenous catheter replacement strategies. Infection 33:96–97PubMedCrossRef

Tagalakis V, Kahn SR, Libman M et al (2002) The epidemiology of peripheral vein infusion thrombophlebitis: a critical review. Am J Med 113:146–151PubMedCrossRef

Myrianthefs P, Sifaki M, Samara I et al (2005) The epidemiology of peripheral vein complications: evaluation of the efficiency of differing methods for the maintenance of catheter patency and thrombophlebitis prevention. J Eval Clin Pract 11:85–89PubMedCrossRef

Lanbeck P, Odenholt I, Paulsen O (2003) Dicloxacillin: a higher risk than cloxacillin for infusion phlebitis. Scand J Infect Dis 35:397–400PubMedCrossRef

Suga Y, Kumazaki M, Nishigami J et al (2009) Improvement of epirubicin-induced phlebitis to switch from liquid preparation to lyophilized formulation. Gan To Kagaku Ryoho 36:93–96PubMed

Simamora P, Pinsuwan S, Alvarez JM et al (1995) Effect of pH on injection phlebitis. J Pharm Sci 84:520–521PubMedCrossRef

Kilic B, Kruse M, Stahlmann R (2006) The in vitro effects of quinupristin/dalfopristin, erythromycin and levofloxacin at low concentrations on the expression of different cell adhesion molecules on the surface of endothelial cells (Eahy926). Toxicology 218:30–38PubMedCrossRef

Curran CF, Luce JK, Page JA (1990) Doxorubicin-associated flare reactions. Oncol Nurs Forum 17:387–389PubMed

Juergens R, Brahmer J, Ettinger D (2007) Gemcitabine and vinorelbine in recurrent advanced non-small cell lung cancer: sequence does matter. Cancer Chemother Pharmacol 59:621–629PubMedCrossRef

10.

Kelly K, Crowley J, Bunn PA Jr et al (2001) Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 19:3210–3218PubMed

11.

Yoh K, Niho S, Goto K et al (2007) Randomized trial of drip infusion versus bolus injection of vinorelbine for the control of local venous toxicity. Lung Cancer 55:337–341PubMedCrossRef

12.

de Lemos ML (2005) Vinorelbine and venous irritation: optimal parenteral administration. J Oncol Pharm Pract 11:79–81PubMedCrossRef

13.

Brimblecombe RW, Duncan WA, Durant GJ et al (1975) The pharmacology of cimetidine, a new histamine H2-receptor antagonist. Br J Clin Pharmacol 53:435–436

14.

Kubecova M, Kolostova K, Pinterova D (2011) Cimetidine: an anticancer drug? Eur J Pharm Sci 42:439–444PubMedCrossRef

15.

Vassilomanolakis M, Koumakis G, Barbounis V et al (2001) Prevention of vinorelbine phlebitis with cimetidine: a two-step design study. Support Care Cancer 9:108–111PubMedCrossRef

16.

Liu FR, Jiang CG, Li YS et al (2011) Cimetidine inhibits the adhesion of gastric cancer cells expressing high levels of sialyl Lewis x in human vascular endothelial cells by blocking E-selectin expression. Int J Mol Med 27:537–544PubMed

17.

Kobayashi K, Matsumoto S, Morishina T et al (2000) Cimetidine inhibits cancer cell adhesion to endothelial cells and prevents metastasis by blocking E-selectin expression. Cancer Res 60(14):3978–3984PubMed

18.

Bevilacqua MP, Stengelin S, Gimbrone MA Jr et al (1989) Endothelial leukocyte adhesion molecule: an inducible receptor for neutrophils related to complement regulatory proteins and lectins. Science 243:1160–1165PubMedCrossRef

19.

Sriramarao P, Norton CR, Borgstrom P et al (1996) E-selectin preferentially supports neutrophil but not eosinophil rolling under condition of flow in vitro and in vivo. J Immunol 157:4672–4680PubMed

20.

Pan D, Han J, Wilburn P, Rockson SG (2006) Validation of a new technique for the quantitation of edema in the experimental setting. Lymphat Res Biol 4:153–158PubMedCrossRef

21.

al-Swayeh OA, Clifford RH, del Soldato P, Moore PK (2000) A comparison of the anti-inflammatory and anti-nociceptive activity of nitroaspirin and aspirin. Br J Pharmacol 129:343–350PubMedCentralPubMedCrossRef

22.

Kuwahara T, Asanami S, Kubo S (1998) Experimental infusion phlebitis: tolerance osmolality of peripheral venous endothelial cells. Nutrition 14:496–501PubMedCrossRef

23.

Kuwahara T, Asanami S, Kubo S (1998) Dilution is effective in reducing infusion phlebitis in peripheral parenteral nutrition: an experimental study in rabbits. Nutrition 14:186–190PubMedCrossRef

24.

Gamble JR, Vadas MA (1988) A new assay for the measurement of the attachment of neutrophils and other cell types to endothelial cells. J Immunol Methods 109:175–184PubMedCrossRef

25.

Yoh K, Niho S, Goto K et al (2007) Randomized trial of drip infusion versus bolus injection of vinorelbine for the control of local venous toxicity. Lung Cancer 55:337–341PubMedCrossRef

26.

de Lemos ML (2005) Vinorelbine and venous irritation: optimal parenteral administration. J Oncol Pharm Pract 11:79–81PubMedCrossRef

27.

Eppihimer MJ, Schaub RG (2001) Soluble P-selectin antagonist mediates rolling velocity and adhesion of leukocytes in acutely inflamed venules. Microcirculation 8:15–24PubMedCrossRef

28.

Lanbeck P, Odenholt I, Riesbeck K (2004) Dicloxacillin and erythromycin at high concentrations increase ICAM-1 expression by endothelial cells: a possible factor in the pathogenesis of infusion phlebitis. J Antimicrob Chemother 53:174–179PubMedCrossRef

29.

Ma LJ, Wang Z, Hu JH (2009) Preventive effect of cimetidine on infusion phlebitis induced by vinorelbine. Pharm Care & Res 9:340–343

30.

Forlow SB, White EJ, Barlow SC et al (2000) Severe inflammatory defect and reduced viability in CD18 and E-selectin double-mutant mice. J Clin Invest 106:1457–1466PubMedCentralPubMedCrossRef

31.

32.

Motsumoto S, Imaeda Y, Umemoto S et al (2002) Cimetidine increases survival of colorectal cancer patients with high levels of sialyl Lewis-X and sialyl Lewis-A epitope expression on tumour cells. Br J Cancer 86:159–160CrossRef

33.

34.

Kawase J, Kobayashi K, Imaeda Y et al (2005) An interesting change of E-selectin in cimetidine administration during anticancer drug use. Gan To Kagaku Ryoho 32:1578–1579PubMed

35.

Kawase J, Ozawa S, Kobayashi K et al (2009) Increase in E-selectin expression in umbilical vein endothelial cells by anticancer drugs and inhibition by cimetidine. Oncol Rep 22:1293–1297PubMed

Title: Cimetidine attenuates vinorelbine-induced phlebitis in mice by militating E-selectin expression
Authors: Zhuo Wang
Lijuan Ma
Xuebin Wang
Heping Cai
Jin Huang
Jiyong Liu
Jinhong Hu
Dingfeng Su
Publication date: 01-08-2014
Publisher: Springer Berlin Heidelberg
Published in: Cancer Chemotherapy and Pharmacology / Issue 2/2014
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-014-2487-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2014

Gastric cancer with para-aortic lymph node metastases: do not miss a chance of cure!

A phase II trial of Cremorphor EL-free paclitaxel (Genexol-PM) and gemcitabine in patients with advanced non-small cell lung cancer

Phase 1 dose-escalation study of the PARP inhibitor CEP-9722 as monotherapy or in combination with temozolomide in patients with solid tumors

Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001)

A phase I study of pegylated liposomal doxorubicin and temsirolimus in patients with refractory solid malignancies

Third-space fluid distribution of pemetrexed in non-small cell lung cancer patients

Keynote webinar | Spotlight on antibody–drug conjugates in cancer